Evidence map›Paper›PMID 42567515›Full record

ArticleThe Journal of biological chemistry2026

Domain-dependent uncoupling of the co-chaperone and E3 ubiquitin ligase CHIP underlies heterogeneity in spinocerebellar ataxia 48.

Selin Altinok, Ethan Paulakonis, Michael F Almeida, Isaac Hwang, Rebekah Sanchez-Hodge, Christina D'Ovidio, Alison S Eidman, Shreesti Shrestha, Georgia Roper, Grant Irons and 13 more

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Selin AltinokThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Ethan PaulakonisDepartment of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Michael F AlmeidaThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Isaac HwangThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Rebekah Sanchez-HodgeThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Christina D'OvidioThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Alison S EidmanDepartment of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Shreesti ShresthaDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Georgia RoperThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Grant IronsThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Elena VargasThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Ivy PengThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Morcos SaeedThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Aliyaa PathanThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Mel N AzinThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Joseph LathamThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Sarah M RonnebaumThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Chang-He ShiInstitute of Neuroscience, Zhengzhou University, Zhengzhou, Henan, China.
Mark J RanekDivision of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
K Matthew ScaglioneDepartment of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA.
Richard C PageDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Nicholas G BrownDepartment of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Electronic address: nbrown1@email.unc.edu.
Jonathan C SchislerThe McAllister Heart Institute, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Department of Pathology and Lab Medicine, and Computational Medicine Program, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Electronic address: schisler@unc.edu.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Pre-doctoral Training Program in Integrative Vascular BiologyT32HL069768 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Christopher P. Mack · 2002 to 2026
$9.7M
Preclinical CoreP50HD103573 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GABRIEL S DICHTER · 2020 to 2026
$9.7M
CHIP: A link between the chaperone &proteasome systemsR01GM061728 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SCHISLER, JONATHAN C. · 2001 to 2013
$3.4M
Dual CHIP Functions Control Tau Triage In Alzheimer's DiseaseR01AG061188 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COHEN, TODD JONATHAN, SCHISLER, JONATHAN C. · 2019 to 2023
$3.1M
Triage mechanisms for directing protein refolding and degradationR35GM128595 · NIGMS · MIAMI UNIVERSITY OXFORD · PI Richard C Page · 2018 to 2026
$2.8M
Protein quality control in age-related diseasesR01AG066710 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SCHISLER, JONATHAN C. · 2020 to 2024
$2.4M
NCI NIH HHS P30 CA016086NHLBI NIH HHS T32 HL069768NIA NIH HHS R01 AG061188NIA NIH HHS R01 AG066710NICHD NIH HHS P50 HD103573NIGMS NIH HHS R01 GM061728NIGMS NIH HHS R35 GM128595
6 · The paper itself

Abstract

The carboxyl terminus of Hsp70-interacting protein (CHIP, encoded by STUB1) combines co-chaperone and E3 ubiquitin ligase activities to regulate protein quality control. Heterozygous mutations in STUB1 cause spinocerebellar ataxia type 48 (SCA48), a progressive cerebellar ataxia with variable extrapyramidal and cognitive features. To understand the molecular basis of this variability, we systematically analyzed 13 SCA48-associated variants spanning the TPR and U-box domains through recombinant protein biochemistry and cellular models. TPR variants retained intrinsic ligase activity but showed significantly reduced HSP70 binding, impaired substrate ubiquitination, and decreased stability. Conversely, U-box variants abolished ligase function, promoted the formation of high-molecular-weight oligomers, and often increased CHIP levels while only partially impairing co-chaperone activity. Many mutants displayed temperature-sensitive defects and defective stress-induced nuclear translocation. Principal component analysis revealed distinct biochemical clustering specific to each domain. RNA-seq following STUB1 knockdown modeled CHIP insufficiency and showed preserved HSF1-dependent transactivation, but loss of CHIP's capacity to amplify ubiquitination, chaperone function, and stress-related transcriptional programs. Meta-analysis of 87 SCA48 patients linked TPR-like biochemical signatures to upper motor neuron involvement and U-box-like profiles to prominent dysarthria. Overall, these data indicate that SCA48 results from domain-specific disruption of CHIP's dual functions, producing varying degrees of CHIP insufficiency and/or gain-of-toxic effects that together contribute to the phenotypic diversity observed across patients. This work refines the mechanistic framework for SCA48 pathogenesis and highlights strategies for therapeutic modulation of residual CHIP activity.

Indexed as

CHIPco-chaperoneE3 ubiquitin ligasegenotype-phenotype correlationheat shock responseHSF1HSP70molecular chaperoneoligomerizationprotein quality controlspinocerebellar ataxia type 48STUB1

Identifiers

PMID42567515
PMCPMC13570301

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.